4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Names and Identifiers
Name | Voriconazole
|
Synonyms | 137234-62-9 Voriconazole rel-(R,R)-Voriconazole Voriconazole Impurity 28 Azilsartan medoxomil impurity318 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol (2R,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyriMidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol rel-(αR,βR)-α-(2,4-Difluorophenyl)-5-fluoro-β-Methyl-α-(1H-1,2,4-triazol-1-ylMethyl)-4-pyriMidineethanol 4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI)
|
CAS | 137234-62-9 137330-52-0 137234-71-0
|
InChI | InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3 |
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Physico-chemical Properties
Molecular Formula | C16H14F3N5O
|
Molar Mass | 349.31 |
Density | 1.42±0.1 g/cm3(Predicted) |
Melting Point | 127-130℃ |
Boling Point | 508.6±60.0 °C(Predicted) |
Specific Rotation(α) | D25 -62° (c = 1 in methanol) |
Flash Point | 261.4°C |
Solubility | Soluble in DMSO, not in water |
Vapor Presure | 3.63E-11mmHg at 25°C |
Appearance | White to light yellow solid powder |
pKa | 11.54±0.29(Predicted) |
Storage Condition | 2-8℃ |
Refractive Index | 1.616 |
MDL | MFCD00905717 |
Physical and Chemical Properties | Melting point 127-130°C |
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Reference
Reference Show more | 1. Wang Xinming, Zhang Zhonglin, Yuan Mingyong. Establishment and application of a new two-dimensional high performance liquid chromatography method for determination of voriconazole concentration in human serum [J]. Journal of Chengdu Medical College, 2019, 14(02):38-42. 2. Chen Jun, Huang Chunxin, Wang Min. Determination of voriconazole in Human Serum by Ultra Performance Liquid Chromatography and Its Clinical Application [J]. Hainan Medicine, 2021,32(02):173-176. |
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Nature
Open Data Verified Data
melting point 127 ~ 130'Cl [al2! 5-62. (c = l methanol).
Last Update:2024-01-02 23:10:35
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Preparation Method
Open Data Verified Data
The methanol solution of a-fluoropropionyl ethyl acetate and formamidine acetate is added to the methanol solution of sodium methoxide to carry out the cyclization reaction, and the material obtained by the reaction is refluxed with phosphorus oxychloride, chlorination gave 4 monochloro -6-ethyl -5-fluoropyrimidine. Dissolve it in tetrahydrofuran and add it Dropwise to the tetrahydrofuran solution of lithium diisopropylamide at a certain temperature, stir and add 1-(2,4-= fluorophenyl) tetrahydrofuran solution of -2-(1H-1,2, 4-triazol-1-yl) ethanone to give 3-(4-chloro-5-fluoropyrimidin-6-yl) one 2 One (2.4 difluorophenyl) one 1 one (1H-1,2.4 -- oxazol-1-yl) butan-2-ol. Dissolve it in ethanol, add palladium-carbon and sodium acetate, hydrodechlorination, and then separate to obtain voriconazole.
Last Update:2022-01-01 09:08:46
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Standard
Authoritative Data Verified Data
This product is (2R,3S)-2-(2, 4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-l-(1H-1,2, 4-triazino-1-yl)-2-butanol. Calculated as the dried product, the content of C16H14F3N50 shall not be less than 98.5%.
Last Update:2024-01-02 23:10:35
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Trait
Authoritative Data Verified Data
- This product is white or off-white powder or crystalline powder.
- This product is soluble in methanol, ethanol, N,N-dimethylformamide, dimethyl sulfoxide, almost insoluble in water.
melting point
The melting point of this product (General 0612) is 127~133°C.
specific rotation
take this product, precision weighing, add ethanol to dissolve and dilute the solution containing about 10 mg per 1 ml, according to the law (General 0621), the specific rotation was -58 ° to -62 °.
Last Update:2022-01-01 11:53:13
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Use
Open Data Verified Data
voriconazole is a second-generation, synthetic fluconazole derivative developed by Pfizer, USA. It was first launched in the United States in August 2002and developed by voriconazole in Pfi-zer. Second generation triazole antifungal agents. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and can be used for the treatment of serious fungal infection. Treatment of immunocompromised patients for potentially fatal infections, including acute invasive aspergillosis, fluconazole-resistant severe invasive candidiasis, and severe fungal infections caused by mycosis postris and Fusarium. Voriconazole was more sensitive than ketoconazole and fluconazole, but slightly less sensitive than itraconazole and terbinafine.
Last Update:2022-01-01 09:08:47
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Differential diagnosis
Authoritative Data Verified Data
- in the chromatogram recorded under the D-isomer, the retention time of the main peak of the test solution should be consistent with the retention time of the voriconazole peak in the system applicable solution.
- take an appropriate amount of this product, dissolve it with ethanol and dilute it to make a solution containing about 25ug per lml, and measure it by UV-Vis spectrophotometry (General rule 0401), there is a maximum absorption at a wavelength of 256nm and a minimum absorption at a wavelength of 231nm.
- The infrared absorption spectrum of this product should be consistent with that of the reference product (General rule 0402).
- This product shows the identification reaction of organic fluoride (General rule 0301).
Last Update:2022-01-01 11:53:13
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Exam
Authoritative Data Verified Data
crystallinity
take the right amount of this product, according to the law inspection (General 0981), should comply with the provisions.
clarity and color of solution
take 5 parts of this product, each 0.lg, put it in Nessler's colorimetric tube, add 5ml of propylene glycol-ethanol (2:3) mixed solution to dissolve, the solution should be clear and colorless (general section 0901 first method and general section 0902 first method).
Related substances
take this product, add mobile phase to dissolve and dilute to make a solution containing about 1 mg per 1ml as a test solution; Take 1ml for precision measurement and put it in a 100ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the chromatographic conditions under the content determination item, the detection wavelength is 251mn, and 10ul of the test solution and the control solution are accurately measured, and the human liquid chromatograph is injected respectively, the chromatogram was recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) the area of the main peak of the control solution, and the sum of the areas of each impurity peak shall not be greater than the area of the main peak of the control solution (1.0%).
d-isomer
take the right amount of this product, precision weighing, plus anhydrous ethanol dissolution and quantitative dilution of about 0.5mg per lml solution, as a test solution; in addition, an appropriate amount of voriconazole dextrorotatory isomer reference substance was accurately weighed, dissolved and quantitatively diluted with mobile phase to prepare a solution containing about 2ug per 1 ml as a reference solution. Test according to high performance liquid chromatography (General 0512). Silica gel bonded with amylose tolylcarbamate] was used as filler (Chiralpak AS-H,4.6mm X 250mm, or column with equivalent performance), and n-hexane-anhydrous ethanol (80:20) was used as mobile phase; the flow rate was 0.5ml per minute and the detection wavelength was 256mn. Take appropriate amount of voriconazole reference and voriconazole dextrorotatory isomer control, add absolute ethanol to dissolve and dilute to make a mixed solution containing voriconazole 0.5mg and voriconazole dextrorotatory isomer in 1 ml, as the system applicable solution, A 20u1 injection liquid chromatograph was used to record the chromatogram. The resolution between voriconazole peak and voriconazole dextrorotatory isomer peak should be greater than 2.0. 20 u1 of the test solution and the reference solution were respectively injected into the human liquid chromatograph, and the chromatograms were recorded. Calculated by peak area according to external standard method, containing voriconazole dextrorotatory isomer shall not exceed 0.5%.
residual solvent
methanol, ethanol, acetone, isopropanol, n-hexane, ethyl acetate, tetrahydrofuran and cyclohexane precision weigh this product about O.lg, top empty bottle, precision add N, N-dimethylformamide 5.0, gently shake to dissolve, sealed, as a test solution; Precision weighing methanol, ethanol, acetone, isopropyl alcohol, N-hexane, ethyl acetate, tetrahydrofuran and cyclohexane each appropriate amount, plus N, N-dimethylformamide dissolution and quantitative dilution made into methanol 60ug, ethanol 100ug, acetone 100ug, isopropanol 100ug, the solution of n-hexane 5.8ug, ethyl acetate 100ug, tetrahydrofuran 14.4ug and cyclohexane 77.6ug was accurately sucked into a headspace bottle and packed as a reference solution. According to the test for determination of residual solvents (General rule 0861, second method), 6% cyanopropylphenyl-94% dimethylpolysiloxane (or similar polarity) is used as the stationary liquid; The initial temperature is 40°C, the temperature was increased to 80°C at a rate of 2°C per minute and then to 230°C at a rate of 30°C for 2 minutes. The inlet temperature was 300°C, the detector temperature was 300°C; The headspace bottle equilibrium temperature was 80°C, the equilibrium time was 30 minutes, and the split ratio was 15:1. The test solution and the reference solution were injected by Headspace, and the chromatograms were recorded. The peak area shall be calculated according to the external standard method and shall comply with the regulations.
dichloromethane and chloroform
take this product about 0.lg, precision weighing, precision add N, N-dimethylformamide 1.0, gently shake to dissolve, as a test solution; the appropriate amount of methylene chloride and chloroform was accurately weighed, and N, N-dimethylformamide was added to dissolve and dilute to prepare a solution containing 60ug of methylene chloride and 6.0ug of chloroform per 1 ml, which was used as a reference solution. According to the test for determination of residual solvents (General Principle 0861 third method), 6% cyanopropyl phenyl-94% dimethyl polysiloxane (or similar polar) is used as the stationary liquid, and the electron capture detector (ECD) is used; the initial temperature was 60°C, maintained for 7 minutes, and the temperature was increased to 250°C at a rate of 50°C per minute for 20 minutes. The inlet temperature was 300°C, the detector temperature was 300°C, and the split ratio was 2:1; The reference solution and the test solution were injected with 1 u1, and the chromatogram was recorded. The peak area shall be calculated according to the external standard method and shall comply with the regulations.
fluorine
take this product 12mg, precision weighing, according to the fluorine inspection method (General 0805) inspection, fluorine content should be 14.6% ~ 16.3%.
chlorine-containing compounds
take about 20mg of this product, according to the oxygen flask combustion method (General rule 0703) for organic destruction, 0.4% sodium hydroxide solution 20ml as the absorption liquid, the absorption liquid is neutralized with dilute nitric acid 10ml, move to a 50ml Nessler cuvette and check with the control solution according to the chloride test method (General rule 0801) (operate in the same manner as the test sample, but do not contain the test sample in the filter paper during combustion, and add standard sodium chloride solution 6.oml) comparison, not more concentrated (0.3%).
loss on drying
take this product, at 80°C under reduced pressure drying to constant weight, weight loss should not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 20 parts per million of heavy metal when examined by law (General rule 0821, Law II).
Last Update:2022-01-01 11:53:14
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with octanoalkylsilane as filler (4.6mm X 250mm,5um or equivalent column); 0.02mol/L ammonium acetate buffer (pH adjusted to 4.0±0.3 with acetic acid)-Fermentation-acetonitrile (55:15:30) as mobile phase; Column temperature was 35°C, detection wavelength was 256Nm. Weigh an appropriate amount of voriconazole, add the mobile phase to dissolve and dilute to make a solution containing about 0.5mg per lml, place in a water bath at 100°C for 40 minutes, cool to room temperature, inject 10ul into human liquid chromatograph, record the chromatogram, the degree of separation between two impurity peaks with a relative retention time of about 0.2 to 0.4 should be greater than 1.5.
assay
take the right amount of this product, precision weighing, plus mobile phase dissolution and quantitative dilution made in each lml containing about 0.lmg solution, precise amount of lOul, injected into the liquid chromatograph, record the chromatogram; Another appropriate amount of voriconazole control, precision weighing, plus mobile phase dissolution and quantitative dilution to make about 0 per lml. lmg solution, the same method of determination, according to the external standard method to calculate the peak area, that is.
Last Update:2022-01-01 11:53:15
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Category
Authoritative Data Verified Data
Last Update:2022-01-01 11:53:15
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Storage
Authoritative Data Verified Data
sealed and stored in a dry place.
Last Update:2022-01-01 11:53:15
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Voriconazole Tablets
Authoritative Data Verified Data
This product contains voriconazole (C16H14F3N5O) should be 95.0% to 105.0% of the label.
trait
This product is a film-coated tablet, white or off-white after removal of the coating.
identification
- in the chromatogram recorded under the D-isomer, the retention time of the main peak of the test solution should be consistent with the retention time of the voriconazole peak in the system applicable solution.
- take an appropriate amount of this product, add ethanol to dissolve and dilute to make a solution containing about 25ug voriconazole per lml, and measure it by UV-Vis spectrophotometry (General 0401), there is a maximum absorption at a wavelength of 256nm and a minimum absorption at a wavelength of 231nm.
examination
- Related Substances: take an appropriate amount of fine powder of this product, dissolve it with mobile phase and dilute it to make a solution containing about 1 mg of voriconazole per 1 ml, which is used as a test solution; Take 1 ml for precision measurement, set in a 100ml measuring flask, dilute to the scale with the mobile phase, and shake to serve as a control solution. According to the chromatographic conditions under the content determination item, the detection wavelength is 251nm, and the sample solution and the control solution are 10 u1 respectively, and the human liquid chromatograph is injected respectively, the chromatogram was recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) the area of the main peak of the control solution, and the sum of the areas of each impurity peak shall not be greater than the area of the main peak of the control solution (1.0%).
- d-isomer precision weighing appropriate amount of fine powder of this product, adding anhydrous ethanol to dissolve and dilute to prepare a solution containing about 0.5mg of voriconazole per 1 ml as a test solution; in addition, an appropriate amount of voriconazole dextrorotatory isomer reference substance was accurately weighed, dissolved and diluted with mobile phase to prepare a solution containing about 2% per 1 ml as a reference solution. The assay was performed according to the method under the right-handed isomer examination of voriconazole. The content of voriconazole dextrorotatory isomer shall not exceed 0.5% of the labeled amount calculated by peak area according to external standard method.
- dissolution of this product, according to the dissolution and release determination method (General 0931 second method), with 0.900ml of lmol/ L hydrochloric acid solution is the dissolution medium, and the rotation speed is 50 revolutions per minute. The operation is carried out according to law. After 30 minutes, the appropriate amount of the solution is taken, filtered, and 10ml of the continued filtrate is accurately taken, in a 25ml measuring flask, use 0. Dilute the lmol/ L hydrochloric acid solution to the scale, shake well, measure the absorbance at the wavelength of 256nm according to UV-visible spectrophotometry (General rule 0401); another precision weighing voriconazole control about llmg, 100ml flask, add 0.1 mol/ L hydrochloric acid solution dissolved and diluted to the scale, shake, precision take 5ml, put 25ml flask, with 0.1 mol/ L hydrochloric acid solution diluted to the scale, shake, the same method to calculate the dissolution of each tablet. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler (4.6mm X 250mm , 5um or performance equivalent column); the mobile phase was 0.02mol/L ammonium acetate buffer (adjusted to pH 4.0±0.3 with acetic acid)-methanol-acetonitrile (55:15:30); The column temperature was 35°C, and the detection wavelength was 256nm. Weigh an appropriate amount of voriconazole, add the mobile phase to dissolve and dilute to make a solution containing about 0.5mg per lml, place in a water bath at 100°C for 40 minutes, cool to room temperature, inject 10u1 into the liquid chromatograph, record the chromatogram, the degree of separation between two impurity peaks with a relative retention time of about 0.2 to 0.4 should be greater than 1.5.
- determination of 20 tablets of this product, precision weighing, fine grinding, precision weighing an appropriate amount (about equivalent to voriconazole 0.lg), put in a 100ml measuring flask, add mobile phase to dissolve voricontron and dilute to scale, shake well, filter, Take 5ml of continuous filtrate precisely, put it in 50ml measuring flask, dilute to scale with mobile phase, shake well, take 10ul accurately, inject human liquid chromatograph, record chromatogram; Take the appropriate amount of voriconazole reference substance, precision weighing, add mobile phase dissolution and quantitative dilution to make about 0 in 1 ml. lmg solution, the same method for determination. According to the external standard method to calculate the peak area, that is.
category
same with voriconazole.
specification
50mg
storage
sealed and stored in a dry place.
Last Update:2022-01-01 11:53:17
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (R*,R*)- (9CI) - Voriconazole capsules
Authoritative Data Verified Data
This product contains voriconazole (C16H14F3N50) should be labeled the amount of 95.0% to 105.0%.
trait
The content of this product is white or white particles.
identification
- in the chromatogram recorded under the D-isomer, the retention time of the main peak of the test solution should be consistent with the retention time of the voriconazole peak in the system applicable solution.
- take an appropriate amount of the contents of this product, add ethanol to dissolve and dilute to make a solution containing 25ug voriconazole per lml, filter, and take the filtrate according to UV-Vis spectrophotometry (General 0401) it was determined that there was a maximum absorption at a wavelength of 256nm and a minimum absorption at a wavelength of 231nm.
examination
- appropriate amount of fine powder under the content determination item of related substances is dissolved by adding mobile phase and diluted to prepare a solution containing about 1 mg of voriconazole per 1ml, which is used as a test solution; 1ml for precision measurement, set in a 100ml measuring flask, dilute to the scale with the mobile phase, and shake to serve as a control solution. According to the chromatographic conditions under the content determination item, the detection wavelength is 251nm, and the test solution and the control solution are respectively injected into the liquid chromatograph, the chromatogram was recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.5%) the area of the main peak of the control solution, and the sum of the areas of each impurity peak shall not be greater than the area of the main peak of the control solution (1.0%).
- dextrorotatory isomer an appropriate amount of fine powder of the contents of this product is precisely weighed, dissolved and diluted with anhydrous ethanol to prepare a solution containing about 0.5mg of voriconazole per 1 ml as a test solution; in addition, an appropriate amount of voriconazole dextrorotatory isomer control was accurately weighed, dissolved and diluted with mobile phase to prepare a solution containing about 2ug per 1 ml as a control solution.
the content of voriconazole dextrorotatory isomer shall not exceed 0.5% of the labeled amount as determined by the method under voriconazole dextrorotatory isomer examination and calculated by peak area according to external standard method.
- dissolution of this product, according to the dissolution and release determination method (General 0931 first method), with 0.100ml of lmol/ L hydrochloric acid solution is the dissolution medium, and the rotation speed is rpm. The operation is carried out according to law. After 30 minutes, the appropriate amount of the solution is taken, filtered, and 10ml of the continued filtrate is accurately taken, in a 25ml measuring flask, use 0. Dilute the lmol/ L hydrochloric acid solution to the scale, shake well, measure the absorbance at the wavelength of 256nm according to UV-visible spectrophotometry (General rule 0401); another precision weighing voriconazole control about llmg, 100ml flask, add 0.1 mol/ L hydrochloric acid solution dissolved and diluted to the scale, shake, precision take 5ml, put 25ml flask, with 0.1 mol/ L hydrochloric acid solution diluted to the scale, shake, the same method to calculate the amount of each dissolution. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0103).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler (4.6mm X 250mm , 5um or equivalent performance column; the mobile phase was 0.02 mol/ L ammonium acetate buffer (adjusted to pH 4.0±0.3 with acetic acid)-methanol-acetonitrile (55:15:30); The column temperature was 35°C, the detection wavelength was 256Nm. Weigh an appropriate amount of voriconazole, add the mobile phase to dissolve and dilute to make a solution containing about 100 mg per 1 ml, place in a water bath at 100°C for 40 minutes, cool to room temperature, take a injection liquid chromatograph, record the chromatogram, the degree of separation between two impurity peaks with a relative retention time of about 0.2 to 0.4 should be greater than 1.5.
- determination of content under the item of loading difference, mixed evenly, finely ground, accurately weigh appropriate amount, add mobile phase to dissolve voriconazole and quantitatively dilute to make voriconazole in about 0 ml. lmg solution, 10 u1 was accurately measured, injected into the liquid chromatograph, and the chromatogram was recorded. Another appropriate amount of voriconazole reference substance was accurately weighed, dissolved and quantitatively diluted with mobile phase to make about 0 in each lml. lmg solution, the same method for determination. According to the external standard method to calculate the peak area, that is.
category
same with voriconazole.
specification
50mg
storage
sealed and stored in a dry place.
Last Update:2022-01-01 11:53:18